ClinicalTrials.gg
RecruitingNCT07293780Updated Nov 2, 2026

Effect of TMS on Neuropathic Pain for Patients With Spinal Cord Injury

An interventional study of active rTMS of M1 and sham TMS in Spinal Cord Injury and Neuropathic Pain, sponsored by Ankara Etlik City Hospital. Recruiting at 2 sites in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Ankara Etlik City Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 2, 2026Primary completion movedStudy completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 62 studies in Spinal Cord Injuries with a site in Turkey — 16 open to participants now, 18 under way, 1 of them phase 3. Spinal Cord Injuries · Turkey.

Planned enrollment
13th of 31
39 · median 34
Started
2025
with 10 others
No phase
29 of 62
10 open now
Primary completion
2027-05
later than 16 of 17 live
Registered
45th of 62
by date
Lead sponsor
1 of 62
Ankara Etlik City Hospital

Among the 62 studies in Spinal Cord Injuries with a site in Turkey, this one is the 13th largest by planned enrollment of the 31 interventional ones that give a count, is one of 11 that started in 2025, is one of 29 with no phase, reaches primary completion later than 16 of the 17 other live ones, and was the 45th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

16 of the 62 studies in Spinal Cord Injuries with a site in Turkey are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Spinal Cord Injuries with a site in Turkey, or all of them as a file.
02

Study summary

Patients will be randomly assigned to three groups using a randomization scheme: active primary motor cortex (M1) rTMS, active anterior cingulate cortex (ACC) rTMS, or sham M1 rTMS. Stimulation will be delivered using a Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, UK) with figure-of-eight active and sham coils or a double-cone coil, depending on the treatment group. All patients will receive 10 sessions of 5 Hz rTMS over two weeks under physician supervision. Stimulation intensity will be set at 90% of the resting motor threshold (RMT), determined from the contralateral first dorsal interosseous muscle following stimulation of the dominant hemisphere. Each session will consist of 10 trains of stimulation separated by 50-second intervals, delivering a total of 500 pulses. All patients will continue their conventional physical therapy programs throughout the study.

Read the detailed description

This study will be designed as a randomized, double-blind, sham-controlled clinical trial. Eligible patients will be randomly allocated to one of three groups using a computer-generated randomization sequence: active primary motor cortex (M1) repetitive transcranial magnetic stimulation (rTMS), active anterior cingulate cortex (ACC) rTMS, or sham M1 rTMS.

Stimulation will be performed at Etlik City Hospital and Ankara Gaziler Physical Medicine and Rehabilitation Training and Research Hospital using a Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, Dyfed, UK). Active and sham figure-of-eight coils will be used for M1 stimulation, while a double-cone coil will be used for ACC stimulation.

All participants will undergo 10 rTMS sessions over two consecutive weeks, with five sessions per week, under physician supervision. In the active and sham M1 groups, stimulation will target the lower extremity representation of the primary motor cortex using active or sham stimulation according to group allocation. In the active ACC group, stimulation will target the anterior cingulate cortex. The stimulation frequency will be 5 Hz, and stimulation intensity will be set at 90% of the resting motor threshold (RMT), determined from the contralateral first dorsal interosseous (FDI) muscle following stimulation of the dominant hemisphere. Each session will consist of 10 trains of 5 Hz stimulation, separated by 50-second inter-train intervals, delivering a total of 500 pulses per session.

The study will employ a double-blind design in which participants and outcome assessors will remain unaware of treatment allocation throughout the study. The physician administering rTMS will be aware of group assignments but will not participate in outcome assessments. All participants will continue their conventional physical therapy programs throughout the intervention period.

This design aims to compare the effects of stimulation targeting different cortical regions on clinical outcomes while minimizing potential bias associated with treatment expectations and outcome assessment.

03

Conditions studied

  • Spinal Cord Injury
  • Neuropathic Pain

Keywords

  • repetitive transcranial magnetic stimulation
  • anterior cingulate cortex
04

Who can participate

The criteria were revised on the registry on Nov 2, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients for whom at least 12 months have passed since the date of the spinal cord injury
  2. Patients who meet the International Spinal Cord Injury Pain (ISCIP) Classification criteria for central neuropathic pain below the level of the lesion and who have had pain for at least 6 months
  3. Patients aged 18-65
  4. Pain not attributable to other causes such as rheumatological diseases or diabetes
  5. Patients with VAS > 4 despite maximum dose of pharmacological agents (anticonvulsants, antidepressants, opioids), exercise and physical therapy agents, taking into account renal function tests and other comorbidities

Exclusion criteria

Exclusion Criteria:

  1. History of epilepsy
  2. Metallic implant in the scalp
  3. Cochlear implant
  4. Spinal cord stimulator
  5. Pacemaker
  6. Presence of psychiatric illness
  7. Pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
39 participants (estimated)

Study arms

  • Active comparator
    active rTMS primary motor cortex

    rTMS at 5 Hz targeting the M1 area of the lower extremity motor area under medical supervision for a total of 10 sessions over 2 weeks with 8- coil.

    Device: active rTMS of M1

  • Experimental
    rTMS anterior cingulate gyrus

    Active 5 Hz rTMS targeting the anterior cingulate cortex for a total of 10 sessions over 2 weeks under medical supervision with double cone coil.

    Device: active rTMS of anterior cingulate cortex

  • Sham comparator
    sham rTMS primary motor cortex

    sham rTMS at 5 Hz targeting the M1 area of the lower extremity motor area under medical supervision for a total of 10 sessions over 2 weeks with sham 8 coil.

    Device: sham TMS

Interventions

  • Deviceactive rTMS of M1

    Patients in the active primary motor cortex rTMS group will receive active rTMS at 5 Hz targeting the M1 area of the lower extremity motor area under medical supervision for a total of 10 sessions over 2 weeks with 8 coil. The stimulation frequency will be 5 Hz, and stimulation intensity will be set at 90% of the resting motor threshold (RMT), determined from the contralateral first dorsal interosseous (FDI) muscle following stimulation of the dominant hemisphere. Each session will consist of 10 trains of 5 Hz stimulation, separated by 50-second inter-train intervals, delivering a total of 500 pulses per session.

  • Devicesham TMS

    Patients in the sham primary motor cortex rTMS group will receive sham rTMS at 5 Hz targeting the M1 area of the lower extremity motor area under medical supervision for a total of 10 sessions over 2 weeks with sham 8-coil. The stimulation frequency will be 5 Hz, and stimulation intensity will be set at 90% of the resting motor threshold (RMT), determined from the contralateral first dorsal interosseous (FDI) muscle following stimulation of the dominant hemisphere. Each session will consist of 10 trains of 5 Hz stimulation, separated by 50-second inter-train intervals, delivering a total of 500 pulses per session.

  • Deviceactive rTMS of anterior cingulate cortex

    Patients in the active anterior cingulate cortex rTMS group will also receive active 5 Hz rTMS targeting the anterior cingulate cortex for a total of 10 sessions over 2 weeks under medical supervision with double cone coil. The stimulation frequency will be 5 Hz, and stimulation intensity will be set at 90% of the resting motor threshold (RMT), determined from the contralateral first dorsal interosseous (FDI) muscle following stimulation of the dominant hemisphere. Each session will consist of 10 trains of 5 Hz stimulation, separated by 50-second inter-train intervals, delivering a total of 500 pulses per session.

06

What researchers measure

Primary outcomes

  1. visual analog scale - daytime

    The assessment of pain using a 10 cm visual analogue scale (VAS), separately for daytime and night-time. The assessment will be conducted on a scale of "0 = no pain" to "10 = the most severe pain imaginable".

    Time frame: Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)

  2. visual analog scale - night

    The assessment of pain using a 10 cm visual analogue scale (VAS), separately for daytime and night-time. The assessment will be conducted on a scale of "0 = no pain" to "10 = the most severe pain imaginable".

    Time frame: Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)

Secondary outcomes

  1. neuropathic pain scale

    Neuropathic Pain Scale (NPS) will be used to assess the severity and characteristics of neuropathic pain. The scale consists of 10 items evaluating pain intensity, unpleasantness, and specific pain qualities, including sharp, burning, dull, cold, sensitive, and itchy sensations, as well as deep and superficial pain. Each item is scored from 0 to 10, with a total score ranging from 0 to 100. Higher scores indicate greater neuropathic pain severity.

    Time frame: Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)

  2. Beck Depression Inventory

    Beck Depression Inventory (BDI) will be used to assess the severity of depressive symptoms. The inventory consists of 21 self-reported items evaluating cognitive, emotional, and somatic symptoms of depression. Each item is scored from 0 to 3, yielding a total score ranging from 0 to 63, with higher scores indicating greater severity of depressive symptoms.

    Time frame: Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)

  3. Patient satisfaction

    Patient satisfaction will be assessed using a 5-point Likert scale, ranging from 1 (very dissatisfied) to 5 (very satisfied), with higher scores indicating greater patient satisfaction.

    Time frame: End of treatment (week 2), 4 week after end of treatment (week 6), 12 week after end of treatment (week 14)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The data supporting this study's findings can be obtained from the corresponding author upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for May 2027, 16 months after the start.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 16 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Aug 2026 → May 2027 and completion Nov 2026 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Dec 19, 2025
StartActual
Dec 15, 2025
Primary completionEst.
May 1, 2027was Aug 2026
CompletionEst.
Aug 1, 2027was Nov 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 1, 2026→May 1, 2027
Nov 2, 2026
Study completion
Nov 1, 2026→Aug 1, 2027
Nov 2, 2026
Eligibility
3 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedPatients for whom at least 12 months have passed since the date of the eventspinal cord injury
  • EditedPatients who meet the International Spinal Cord Injury Pain Working Group's(ISCIP) Classification criteria for central neuropathic pain below the level of the lesion and who have had pain for at least 6 months
  • EditedPatients with VAS > 4 despite maximum dose of pharmacological agents (anticonvulsants, antidepressants, narcoticsopioids), exercise and physical therapy agents, taking into account renal function tests and other comorbidities
Nov 2, 2026
Interventions
Added Device: active rTMS of M1·Device: active rTMS of anterior cingulate cortex; removed Device: active TMS. Arm changed active rTMS primer motor cortex→active rTMS primary motor cortex; sham rTMS primer motor cortex→sham rTMS primary motor cortex
Nov 2, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • Editedvisual analog scale - daytimeTime frame: first day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment → Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)
  • Addedvisual analog scale - nightTime frame: Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)
Nov 2, 2026
Secondary outcomes
2 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • EditedBeck Depression ScaleInventoryTime frame: first day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment → Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)
  • ChangedBefore 5-point Likert scaleNow Patient satisfactionTime frame: first day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment → End of treatment (week 2), 4 week after end of treatment (week 6), 12 week after end of treatment (week 14)
  • Time frameneuropathic pain scalefirst day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment → Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)
  • Descriptionneuropathic pain scale: how it is measured was reworded
Nov 2, 2026
Contact
Study contact changed: •••0000→•••0000; added d•••@yahoo.com · •••0000. See the current contact
Nov 2, 2026
Title
Effect of TMS on Neuropathic Pain for Patients With SciSpinal Cord Injury
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Aug 1, 2026→May 1, 2027
    Study completion Nov 1, 2026→Aug 1, 2027
    Eligibility 3 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedPatients for whom at least 12 months have passed since the date of the eventspinal cord injury
    • EditedPatients who meet the International Spinal Cord Injury Pain Working Group's(ISCIP) Classification criteria for central neuropathic pain below the level of the lesion and who have had pain for at least 6 months
    • EditedPatients with VAS > 4 despite maximum dose of pharmacological agents (anticonvulsants, antidepressants, narcoticsopioids), exercise and physical therapy agents, taking into account renal function tests and other comorbidities
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • Editedvisual analog scale - daytimeTime frame: first day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment → Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)
    • Addedvisual analog scale - nightTime frame: Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)
    Secondary outcomes 2 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • EditedBeck Depression ScaleInventoryTime frame: first day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment → Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)
    • ChangedBefore 5-point Likert scaleNow Patient satisfactionTime frame: first day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment → End of treatment (week 2), 4 week after end of treatment (week 6), 12 week after end of treatment (week 14)
    • Time frameneuropathic pain scalefirst day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment → Baseline, Change from baseline to end of treatment (week 2), Change from baseline to 4 week after end of treatment (week 6), Change from baseline to 12 week after end of treatment (week 14)
    • Descriptionneuropathic pain scale: how it is measured was reworded
    Interventions Added Device: active rTMS of M1·Device: active rTMS of anterior cingulate cortex; removed Device: active TMS. Arm changed active rTMS primer motor cortex→active rTMS primary motor cortex; sham rTMS primer motor cortex→sham rTMS primary motor cortex
    Contact Study contact changed: •••0000→•••0000; added d•••@yahoo.com · •••0000. See the current contact
    Title Effect of TMS on Neuropathic Pain for Patients With SciSpinal Cord Injury
    + 4 other changes: verification date, description, conditions and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07293780
Responsible party
Ayse Naz Kalem (PM&R Specialist, Ankara Etlik City Hospital) — Principal investigator
First posted
Dec 19, 2025
Start date
Dec 15, 2025
Primary completion
May 1, 2027 (estimated)
Completion
Aug 1, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Ayşe Naz Kalem Özgen, specialist
Contact
kalemnaz@gmail.com
+90 312 797 00 00
Ece Ünlü Akyüz, Specialist
Contact
dreceunlu@yahoo.com
+90 312 797 00 00
Ayşe Naz Kalem, Specialist
principal investigator · Ankara Etlik City Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion